Cardiavent, Inc. researchers were the first to elucidate novel actions of vitamin D receptor activator [CARD-024] in the regulation of renal and cardiovascular function and health. Preclinical and Phase 1 human studies of CARD-024 demonstrated biologic activity without toxic hypercalcemia. Potential best-in-class treatment for hyperparathyroidism and hypertension. Rapid development pathway is attractive for 'Big Pharma' partnering/acquisition.